An ex vivo human model for safety assessment of immunotoxicity of engineered nanomaterials
J. Blersch, B. Kurkowsky, A. Meyer-Berhorn, A. K. Grabowska, E. Feidt, E. Junglas, W. Roth, D. Stappert, A. Kuebelbeck, P. Denner, E. Fava
This paper introduces an ex vivo human model using PBMCs to assess immunotoxicity of engineered nanomaterials through high-throughput, automated assays with dose-response data and multiparametric readouts.
bioRxiv · Jun 29, 2023 · PreprintImmunology